FluMist manufacturing facility cited
Executive Summary
FDA issues MedImmune a warning letter citing the company for manufacturing deficiencies at its Liverpool, U.K. facility, including failure to implement a program to control microbial contamination of eggs used to make FluMist. FDA does not expect lower availability of the flu vaccine for the 2007-2008 flu season, unlike the 2004-2005 season when GMP violations by Chiron caused a shortage...